{
    "root": "300b1924-9cd1-f043-e063-6294a90a25f7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250311",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B"
        }
    ],
    "indications": "Ondansetron is indicated for the prevention of nausea and vomiting associated with:\n                  \n                     highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m\n  \n   2\n                     \n                     initial and repeat courses of moderately emetogenic cancer chemotherapy\n                     radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\n                  \n                  Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications": "See full prescribing information for the recommended dosage in adults and pediatrics. ( 2 ) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "Ondansetron Tablets, USP\n                  \n                  \n                     4 mg (ondansetron hydrochloride, USP (dihydrate) equivalent to 4 mg of ondansetron), are white, oval, standard convex, film-coated tablets with ‘4’ on one side and ‘G1’ logo on the other side in:\n                     Bottles of 30 tablets (NDC 68462-105-30).\n                     Carton of 3 tablets (contains 1 card of 3 unit-of-use blisters) NDC 68462-105-33.\n                     8 mg (ondansetron hydrochloride, USP (dihydrate) equivalent to 8 mg of ondansetron), are yellow, oval, standard convex, film-coated tablets with ‘8’ on one side and ‘G1’ logo on the other side in:\n                     Bottles of 30 tablets (NDC 68462-106-30).\n                     Carton of 3 tablets (contains 1 card of 3 unit-of-use blisters) NDC 68462-106-33\n                  \n                  \n                     Bottles: Store at 20ºC to 25ºC (68ºF to 77ºF) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP.\n                  \n                  \n                     Cartons: Store at 20ºC to 25ºC (68ºF to 77ºF) [see USP Controlled Room Temperature]. Protect from light. Store blister in carton.\n                  \n                  \n                     Ondansetron Orally Disintegrating Tablets, USP\n                  \n                  \n                     4 mg (as 4 mg ondansetron base) are white, circular, flat faced, uncoated tablets with ‘G’ engraved on one side and ‘4’ on the other side in:\n                     Carton of 30 tablets (contains 3 cards of 10 unit-of-use blisters) NDC 68462-157-13\n                     8 mg (as 8 mg ondansetron base) are white, circular, flat faced, uncoated tablets with ‘G’ engraved on one side and ‘8’ on the other side in:\n                     Carton of 10 tablets (contains 1 card of 10 unit-of-use blisters) NDC 68462-158-11\n                     Carton of 30 tablets (contains 3 cards of 10 unit-of-use blisters) NDC 68462-158-13\n                  \n                  \n                     Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Ondansetron is contraindicated in patients:\n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   \n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness"
}